Researchers at Hokkaido University in Japan, in a collaboration with American scientists, may have identified neural crosstalk as the mechanism that drives widespread inflammation in inflammatory diseases, such as rheumatoid arthritis (RA), psoriasis and atherosclerosis.
A rheumatoid arthritis drug developed by Genentech proved to be effective in benefitting patients who have Covid-19-associated pneumonia, according to new late-stage clinical trial data.
Top 200 Medicines Annual Report 2019: The king of medicinesAnkylosing Spondylitits, August 2019, Autoimmune Diseases, Biologics, Biosimilars, Blockbusters, Cervical Cancer, Classical Hodgkin Lymphoma, Crohn's Disease, Esophageal Cancer, Forecasts, Gastric Cancer, Head & Neck Cancer, Hepatocellular Carcinoma, Hidradenitis suppurativa, Issue Archives, Juvenile Idiopathic Arthritis, Market exclusivity, Melanoma, Merkel cell carcinoma, Metastatic Urothelial Carcinoma (mUC), Microsatellite instability-high (MSI-H) cancer, Monoclonal Antibodies, Non-Small Cell Lung Cancer (NSCLC), Plaque Psoriasis, Primary lediastinal large B-cell lymphoma, Product Launches, Psoriatic Arthritis, Renal Cell Carcinoma (RCC), Rheumatoid Arthritis, Therapeutics, Top 200 Medicines, Ulcerative Colitis, Uveitis
Humira’s dominance continues as the world’s top-selling prescription product as the biologic therapy is the first drug to exceed $20 billion in annual global sales.
The U.S. FDA approved Pfizer’s blockbuster drug Xeljanz to treat adults with moderate-to-severe active ulcerative colitis.
The U.S. Food and Drug Administration approved Pfizer Inc.’s second biosimilar to Johnson & Johnson’s blockbuster rheumatoid arthritis drug Remicade.
The FDA approved Boehringer Ingelheim Pharmaceuticals’ Cyltezo, a biosimilar to Humira, in a pre-filled syringe for treating chronic inflammatory diseases.
2017 Annual Report – Top 200 Medicines: Humira Remains Atop The ThroneAnalysts, August 2017, Autoimmune Diseases, Autoimmune Disorders, Biologics, Biosimilars, Blockbusters, Blood Cancers, Breast Cancer, Cervical Cancer, Colorectal Cancer, Forecasts, Forecasts, Gastroenterology, Hepatitis C, Immunology, Inflammatory Diseases, Japan, Kidney Cancer, Mantle Cell Lymphoma (MCL), Multiple Myeloma, Ovarian Cancer, Pneumococcal Disease, Pneumonia, Relapsed Glioblastoma, Rheumatoid Arthritis, Rheumatology, Special Reports, Therapeutics, Top 200 Medicines, Tumor Necrosis Factor (TNF) Inhibitors, Ulcerative Colitis, Vaccines, Vasculitis
AbbVie’s biologic therapy Humira for autoimmune disorders continues to dominate the sales landscape; Gilead’s once-daily hepatitis C treatment Harvoni in 2016 repeated its performance as the world’s second-best-selling prescription medicine.
U.S. drugmaker AbbVie Inc. reported Q2 2017 earnings that edged past analysts’ expectations, helped by robust demand for the company’s flagship RA drug Humira.
Eli Lilly and Company and Incyte Corporation announced a new pooled analysis of data from eight Olumiant (baricitinib) clinical trials, showing that baricitinib-treated and placebo-treated patients with moderate-to-severe rheumatoid arthritis had similar rates of serious infection incidents.
Janssen-Cilag International NV today announced long-term results from SIRROUND-T, a pivotal Phase 3 study that showed sirukumab improved the signs and symptoms of moderately to severely active rheumatoid arthritis (RA) through 52 weeks of treatment in adult patients with an inadequate response and/or intolerance to anti-tumor necrosis factor (TNF)-alpha treatments.